ABT-089
3 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
3
Ongoing
0
Recruiting
0
Completed
0
Sites
71
Countries
1
Endpoints
6
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 6 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 2 of 6 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
1
1
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
3 of 3
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT00555204Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease | ABT-089 Alzheimer’s disease | mild-to-moderate AD | Ph 2 | Terminated | 42 | Jun 2009 | 1 | |
| NCT00809510A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study | ABT-089 Alzheimer’s disease | Age 55-90 | Ph 2 | Terminated | 22 | Jun 2009 | - | |
| NCT00069849A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease | ABT-089 Alzheimer’s disease | Alzheimer's disease | Ph 2 | Terminated | 8 | - | - |
Showing 1-3 of 3 trials